IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

An Increase in N-Ras Expression is Associated with Development of Hormone Refractory Prostate Cancer in a Subset of Patients

(2013) Pamela Traynor et al.   DISEASE MARKERS

The insulin-like growth factor-I receptor as an oncogene

(2011) Haim Werner et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

(2010) T. B. Dorff et al.   CLINICAL CANCER RESEARCH

Interleukin-6 in bone metastasis and cancer progression

(2010) Tasnim Ara et al.   EUROPEAN JOURNAL OF CANCER

Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis

(2010) T. Berger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Anti-inflammatory drugs, antioxidants, and prostate cancer prevention

(2009) Aditya Bardia et al.   CURRENT OPINION IN PHARMACOLOGY

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

(2009) Frédéric R Santer et al.   ENDOCRINE-RELATED CANCER

Biomarkers for epithelial-mesenchymal transitions

(2009) Michael Zeisberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Periprostatic Adipose Tissue as a Modulator of Prostate Cancer Aggressiveness

(2009) David S. Finley et al.   JOURNAL OF UROLOGY

Inhibition of vimentin or  1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo

(2009) X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

(2009) N J Sullivan et al.   ONCOGENE

aPKC /  promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6

(2009) H. Ishiguro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lipocalin 2 promotes breast cancer progression

(2009) J. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas

(2008) M Colomiere et al.   BRITISH JOURNAL OF CANCER

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

(2008) Sergei Grivennikov et al.   CANCER CELL

Beneficial synergistic interactions of TNF-α and IL-6 in C2 skeletal myoblasts—Potential cross-talk with IGF system

(2008) Nasser Al-Shanti et al.   GROWTH FACTORS

Implications of insulin-like growth factor-I for prostate cancer therapies

(2008) Satoko Kojima et al.   INTERNATIONAL JOURNAL OF UROLOGY

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Prostate inflammation and its potential impact on prostate cancer: A current review

(2007) Jessica Haverkamp et al.   JOURNAL OF CELLULAR BIOCHEMISTRY